Both drugs were approved for the single-drug treatment of relapsed or refractory IDH1 or IDH2 mutated AML patients, based on non-randomized phase II trials [23, 24] in the U.S. and resulted in combined CR rates of 30.2% and 26.1% as oral single agents, respectively (Table 1). The gene discussed is IDH1; the disease is acute myeloid leukemia.